Abstract:Background:Adiponectin is an adipose tissue-derived protein with anti-inflammatory properties. Statins are a class of cholesterol-lowering drugs, widely used for treatment of cardiovascular diseases.Objectives:In the current study, we aimed to assess the effects of simvastatin on serum levels of adiponectin in patients with dyslipidemia, recruited from Ghaem Hospital, Mashhad, Iran.Materials and Methods:A total of 102 patients with dyslipidemia were treated with simvastatin or placebo during a double-blind, cr… Show more
“…More details of the study have been published elsewhere. [ 5 ] Fifty-one patients received 40 mg/day simvastatin for 1 month, and another group (51) received a placebo (same size and color with treatment capsules and filled with starch) for 30 days. After a further 2-week washout period, the patients crossed over to the other form of treatment.…”
Section: Methodsmentioning
confidence: 99%
“…[ 5 ] Statins inhibit the rate-limiting enzyme in cholesterol biosynthesis, hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, and reduce serum low-density lipoprotein cholesterol (LDL-C) levels substantially. [ 5 ] Further to their conventional lipid-modulating effects, statins possess so-called “pleiotropic” properties, which comprise improvement of endothelial function, antioxidant properties, anti-inflammatory properties, plaque stabilization, and inhibition platelet aggregation and thrombus formation. [ 6 ] It has been reported that statins treatment may be associated with an improved Vitamin D status,[ 7 8 9 10 ] but this is not a consistent finding.…”
Background:Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are antihyperlipidemic drugs with an established efficacy in stabilizing atherosclerotic plaques and preventing atherogenesis and reducing cardiovascular events. The purpose of this study was to determine the effect of simvastatin on serum Vitamin D status in dyslipidemic patients as Vitamin D status has an impact on monocyte/macrophage function and may also contribute to cardiovascular risk.Methods:Selected individuals (n = 102) were treated with simvastatin (40 mg/day), or matching placebo in a randomized, double-blind, placebo-controlled, crossover trial. Each treatment period (with simvastatin or placebo) lasted for 30 days and was separated by a 2-week washout phase. Serum Vitamin D concentration was assessed pre- and post-treatment.Results:Seventy-seven completed the trial, noncompliance with the study protocol and drug intolerance or relocation were the causes for drop-out. No significant carry-over effect was observed for the assessed parameters. There was a reduction in the serum levels of low-density lipoprotein cholesterol (P < 0.001), total cholesterol (P < 0.001), and triglycerides (P < 0.05). Nevertheless, simvastatin therapy did not significantly affect serum level of high-density lipoprotein cholesterol and Vitamin D level (P > 0.05).Conclusions:Short-term treatment with simvastatin (40 mg/day) does not have a significant affect on serum levels of Vitamin D.
“…More details of the study have been published elsewhere. [ 5 ] Fifty-one patients received 40 mg/day simvastatin for 1 month, and another group (51) received a placebo (same size and color with treatment capsules and filled with starch) for 30 days. After a further 2-week washout period, the patients crossed over to the other form of treatment.…”
Section: Methodsmentioning
confidence: 99%
“…[ 5 ] Statins inhibit the rate-limiting enzyme in cholesterol biosynthesis, hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, and reduce serum low-density lipoprotein cholesterol (LDL-C) levels substantially. [ 5 ] Further to their conventional lipid-modulating effects, statins possess so-called “pleiotropic” properties, which comprise improvement of endothelial function, antioxidant properties, anti-inflammatory properties, plaque stabilization, and inhibition platelet aggregation and thrombus formation. [ 6 ] It has been reported that statins treatment may be associated with an improved Vitamin D status,[ 7 8 9 10 ] but this is not a consistent finding.…”
Background:Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are antihyperlipidemic drugs with an established efficacy in stabilizing atherosclerotic plaques and preventing atherogenesis and reducing cardiovascular events. The purpose of this study was to determine the effect of simvastatin on serum Vitamin D status in dyslipidemic patients as Vitamin D status has an impact on monocyte/macrophage function and may also contribute to cardiovascular risk.Methods:Selected individuals (n = 102) were treated with simvastatin (40 mg/day), or matching placebo in a randomized, double-blind, placebo-controlled, crossover trial. Each treatment period (with simvastatin or placebo) lasted for 30 days and was separated by a 2-week washout phase. Serum Vitamin D concentration was assessed pre- and post-treatment.Results:Seventy-seven completed the trial, noncompliance with the study protocol and drug intolerance or relocation were the causes for drop-out. No significant carry-over effect was observed for the assessed parameters. There was a reduction in the serum levels of low-density lipoprotein cholesterol (P < 0.001), total cholesterol (P < 0.001), and triglycerides (P < 0.05). Nevertheless, simvastatin therapy did not significantly affect serum level of high-density lipoprotein cholesterol and Vitamin D level (P > 0.05).Conclusions:Short-term treatment with simvastatin (40 mg/day) does not have a significant affect on serum levels of Vitamin D.
“…2). Pooled results with only double-blinded, placebo-controlled trials [13–16, 18, 23] retrieved similar results (WMD: -0.15 μg/mL; 95% CI, -0.64–0.34 μg/mL; p = 0.54).Fig. 2Forest plot for the estimation of the effect of simvastatin treatment of serum adiponectin stratified by the treatment duration
…”
Section: Resultsmentioning
confidence: 71%
“…2 ). Pooled results with only double-blinded, placebo-controlled trials [ 13 – 16 , 18 , 23 ] retrieved similar results (WMD: -0.15 μg/mL; 95% CI, -0.64–0.34 μg/mL; p = 0.54). Fig.…”
BackgroundEffects of simvastatin on serum level of adiponectin, a protein conferring benefits in both cardiovascular and metabolic system, are not fully determined.MethodsA meta-analysis of randomized controlled trials (RCTs) was performed. Studies were identified by searching of Pubmed, Embase, and the Cochrane Library databases. Heterogeneity among the RCTs was determined by Cochrane’s Q test and I2 statistics. Meta-analysis was performed with random-effect model or fixed-effect model according to the heterogeneity. Meta-regression and subgroup analyses were performed to analyze the source of heterogeneity.ResultsTwelve RCTs with 16 comparisons and 1042 patients were included. Overall, serum adiponectin was not significantly affected by simvastatin (WMD: 0.42 μg/mL; 95% CI, -0.66–1.50 μg/mL). However, significant heterogeneity was detected (Cochrane’s Q test: p < 0.01; I2 = 83%). Subsequent meta-regression analyses indicated that treatment duration was a significant determinant of the effects of simvastatin treatment on serum adiponectin (Coefficient 0.04, p = 0.03). Subgroup analyses demonstrated that simvastatin treatment was associated with increased adiponectin in studies with treatment duration of 12 weeks (WMD: 3.65 μg/mL; p < 0.01), but not in studies with treatment duration of ≤ 8 weeks (WMD: -0.20 μg/mL; p = 0.38). The different between the two stratums was significant (p < 0.01).ConclusionsTreatment with simvastatin of 12 weeks may increase the serum level adiponectin in patients at risk for cardiovascular diseases, but not for the short term treatment of ≤ 8 weeks.
“…They are very effective agents in both primary and secondary prevention of cardiovascular diseases . Accordingly, statins are now widely used for those indications, with nearly a quarter of the USA adults currently taking a statin, while another 12·8 million could be considered for therapy based on the latest guidelines . Although it has been suggested that statins are relatively safe for prolonged use, there are still concerns that long‐term commitment of individuals to statin could lead to the expression of some deleterious consequences of statins through a cumulative effect over time.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
